AR SB143

Requires Arkansas Medicaid to provide immediate access and reimbursement for new products and label expansions approved by the FDA, or outpatient drugs with federal rebate agreements, when prescribed according to approved or medically accepted indications

Prohibits Arkansas Medicaid from denying or delaying coverage for new products and label expansions solely because the Arkansas Medicaid Drug Utilization Review Board has not completed a formal clinical review

Directs the Department of Human Services to appoint two physicians or advanced practice registered nurses who are licensed in Arkansas and currently treating rare diseases or conditions to the Arkansas Medicaid Drug Utilization Review Board

Authorizes the Department of Human Services to amend rules and bylaws of the Arkansas Medicaid Drug Utilization Review Board to implement these requirements

Addresses the legislative finding that historical delays in Medicaid access to FDA-approved products can cause irreversible harm to patients with life-threatening conditions